Previous close | 4.2000 |
Open | 4.2000 |
Bid | 1.0000 |
Ask | 5.5000 |
Strike | 15.00 |
Expiry date | 2025-01-17 |
Day's range | 4.2000 - 4.2000 |
Contract range | N/A |
Volume | |
Open interest | 9 |
Biogen's (BIIB) acquisition of private biotech, HI-Bio, is set to expand its rare disease pipeline by adding the latter's lead asset, felzartamab.
When you buy shares in a company, there is always a risk that the price drops to zero. But if you pick the right...
PLANEGG/MUNICH, Germany, April 29, 2024--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2024.